Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].

Semiglazov VF, Semiglazov VV, Petrenko OL, Komyakhov AV, Dashyan GA, Paltuev RM, Semiglazova TY, Manikhas AG, Bozhok AA, Lalak IA.

Vopr Onkol. 2015;61(3):381-6. Russian.

PMID:
26242149
2.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.

PMID:
24657003
3.

[HER2-positive breast cancer: standard and double targeted therapy].

Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS.

Vopr Onkol. 2013;59(3):341-6. Russian.

PMID:
23909035
4.

[Possibilities of surgical treatment for disseminated breast cancer].

Bozhok AA, Topuzov ÉÉ, Semiglazov VF, Klimov NA, Kasianova MN, Osianikov AA.

Vopr Onkol. 2013;59(3):320-7. Russian.

PMID:
23909032
5.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

6.

[Use of Taxotere in neoadjuvant therapy of breast cancer].

Semiglazov VV, Donskikh RV, Semiglazova TIu, Bozhok AA, Matsko DE.

Vopr Onkol. 2011;57(5):645-50. Russian.

PMID:
22238937
7.

[Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].

Semilgazov VF, Manikhas AG, Semiglazov VV, Bozhok AA, Dashian GA, Ivanov VG, Paltuev RM, Vasil'ev AG, Shchedrin DE, Ermachenkova AM, Nikitina IV, Pen'kov KD, Bessonov AA, Tabagua TT, Kolar'kova VV.

Vopr Onkol. 2011;57(5):567-77. Review. Russian. No abstract available.

PMID:
22238925
8.

[Decrease of testosterone level in blood of breast cancer patients of reproductive age after neoadjuvant chemotherapy].

Bershteĭn LM, Boriakina MP, Tsyrlina EV, Poroshina TE, Bozhok AA.

Vopr Onkol. 2012;58(5):639-43. Russian.

PMID:
23600280
9.

[Perspectives in use of surgery for disintegrating breast tumor].

Topuzov EE, Sadigova SN, Lemekhov VG, Aristov RL, Danilov AG, Bozhok AA, Kasianova MN, Klimov NA, Topuzov RE.

Vopr Onkol. 2011;57(4):502-4. Russian.

PMID:
22191242
10.

[Possibilities of surgical treatment in disseminated breast cancer].

Bozhok AA, Semiglazov VF, Semiglazov VV, Topuzov EE, Klimov NA.

Vopr Onkol. 2011;57(4):427-33. Review. Russian. No abstract available.

PMID:
22191229
11.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.

Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.

PMID:
21843921
12.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.

Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.

PMID:
20113825
13.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G.

J Clin Oncol. 2009 May 20;27(15):2474-81. doi: 10.1200/JCO.2008.19.2567. Epub 2009 Mar 30.

PMID:
19332727
14.

[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].

Semiglazov VF, Semiglazov VV, Dashian GA, Zhil'tsova EK, Ivanov VG, Bozhok AA, Tonuzov EE, Paltuev RM, Mel'nikova OA, Klettsel' AA, Krivorot'ko PV, Donskikh RV, Kochetova IA, Damenia AO, Zernov KIu, Voskresenskiĭ DA, Bershteĭn LM.

Vopr Onkol. 2007;53(4):400-8. Russian.

PMID:
17969401
15.

[Inflammatory breast carcinoma and prognosticators of efficacy of primary chemotherapy].

Semiglazov VF, Zernov KIu, Bozhok AA, Petrovskiĭ SG, Ivanova OA, Orlov AA, Barash NIu, Paltuev RM, Donskikh RV, Damenia AO, Kletsel' AE, Kochetova IA, Efimenko AV.

Vopr Onkol. 2007;53(1):21-5. Russian.

PMID:
17649729
16.

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM.

Cancer. 2007 Jul 15;110(2):244-54.

17.

[Taxanes in neojuvant radio-, chemoradio- and chemotherapy for breast cancer].

Bozhok AA, Semiglazov VF, Kletzel' AE, Arzumanov AS, Mel'nikova OA, Paltuev RM, Ivanova OA, Semiglazov VV.

Vopr Onkol. 2006;52(1):7-14. Review. Russian. No abstract available.

PMID:
16715697
18.

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.

Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21.

19.

[Prognostic and predictive factors in breast cancer].

Bozhok AA, Semiglazov VF, Semiglazov VV, Arzumanov AS, Klettsel' AE.

Vopr Onkol. 2005;51(4):434-43. Review. Russian.

PMID:
16308974
20.

[Taxotere application in the management of breast cancer].

Bozhok AA, Semiglazov VF, Kletcel' AE, Arzumanov AS, Ivanova OA, Semiglazov VV.

Vopr Onkol. 2005;51(2):253-60. Review. Russian. No abstract available.

PMID:
16223013

Supplemental Content

Loading ...
Support Center